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Abstract
Autoantibodies (autoAbs) against self-proteins have been localized in tumor microenvironment exerting a
complex network of interactions. We reported the presence of autoAbs in breast cancer patients, which promote
tumor progression by activating muscarinic acetylcholine receptors (mAChR) in tumor cells. Cholinergic receptors
are also expressed in dendritic cells (DC) and much clear evidence demonstrated a deficient functional activity of
DC in cancer. Here we investigated whether autoAbs can modulate the expression of maturation markers and the
production of cytokines by DC. IgG from breast cancer patients in stage I reduced the expression of HLA-DR and
CD86 as well as tumor necrosis factor alpha liberation and augmented interleukin IL-12 and IL-10 levels by
cholinergic activation of mature DC. The latter cytokines are also up-regulated in patients’ sera, probably due to
tumor influence, since the addition of breast tumor extract increased cytokine levels in immature DC reaching levels
of mature DC mainly for IL-10 and IL-12. It could be assumed that autoAbs are reinforcing the tolerogenic/
immunosuppressive profile mediated by DC in breast cancer.
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Introduction
Breast cancer is the most common malignant neoplasm and a cause
of death by cancer among women worldwide. Its development
including malignancy grade and patient prognosis is influenced not
only by the mutations that suffer tumor cells, but also by the status of
the immune system, which interacts with tumor microenvironment
[1]. Some authors have reported that the immune system is unable to
halt tumor progression and even more it is responsible of promoting
tumorigenesis [2]. Innate immune cells, like dendritic cells (DC),
natural killer cells, granulocytes, macrophages and monocytes are
present in the normal mammary gland and play an important role
participating in its development and remodeling, but they are also
present in neoplastic tissues, such as breast tumors. This infiltration of
innate immune cells in the tumor tissue might be an attempt of the
body to Fight against illness [3,4]. DC are the most potent professional
antigen presenting cells which can uptake, process, and present
different types of antigens, including tumor antigens to antigen-
specific naïve T cells [5]. DC act as sentinels of the immune system by
efficiently capturing and processing foreign antigens. In the presence
of a “danger signal” (such as infection or inflammation), DC shift from
an antigen-capturing mode to a T-cell sensitizing mode, a
phenomenon called “maturation” which is usually associated with
their migration to secondary lymphoid tissues where they provide
signals 1-3 to T lymphocytes [5]. In most types of cancers or in animal
models of spontaneously arising tumors, instead of being eliminated
by the immune response, tumors progress, metastasize, and ultimately,
result in death of the host. Much clear evidence has demonstrated a
deficient functional activity of DC in cancer [6,7]. Actually, it is
increasingly clear that the DC defects in cancer are systemic, and are
not localized to tumor tissues [8]. Systemic humoral immune response
against different antigens in tumor bearers has been documented [9].
Among these antigens, self-proteins, which are expressed in tumor
cells but not at all or only at very low levels in normal cells might
therefore function as tumor associated antigens capable of priming the
immune system to recognize tumor cells [10]. Therefore, instead of
acting as tumor rejecting antigens, they induce tolerance or
autoimmune responses [11,12]. We have documented that
immunoglobulin G (IgG) from breast cancer patients in T1N0Mx
(tumor size<2 cm, without lymph node metastasis) promotes tumor
cell proliferation, metalloproteinase activity and angiogenesis via
muscarinic acetylcholine receptors (mAChR) activation [13-15]. These
receptors, that are highly expressed in breast tumor cells are
considered as part of the non-neuronal cholinergic system (nNCS)
together with acetylcholine (ACh), choline acetyltransferase and
acetylcholinesterase, the enzymes that synthesize and degrade ACh,
and nicotinic acetylcholine receptors (nAChR), that also target the
action of ACh. We have also reported that nNCS is present in human
DC and that mAChR of 3, 4 and 5 subtypes are expressed and
functional in these cells [16]. Here we investigated the ability of
autoAbs to modulate the expression of maturation markers and the




Cancer patients (n=32) with breast adenocarcinoma in stage I were
selected in the Mastology Department of the Angel H. Roffo Oncology
Institute, University of Buenos Aires, and were classified according to
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TNM criteria as T1N0Mx (tumor size ≤ 2 cm, without axillary node
metastasis). Subjects free of illness (normal) (n=20) were used as
controls. All of them were free of treatment, and blood samples (10-20
ml/donor) were obtained at routine procedures before surgery.
Written informed consent was approved by the Ethics in Research
Committee from the Angel H. Roffo Oncology Institute, and was
obtained from each patient.
IgG purification
After centrifugation of blood samples, sera were separated and heat-
inactivated at 56◦C for 30 min. IgG purification was performed by
affinity chromatography in protein G-agarose (Invitrogen Inc.,
Carlsbad, CA, USA). Samples (pH 6.0-7.5) were loaded onto the
column after equilibrating it with 10 volumes of binding buffer: 0.01
sodium phosphate pH 7.0; 0.15 M NaCl at high salt concentration.
Elution was performed with 0.1 M glycine hydrochloride (pH 2.6) and
adjusted immediately to pH 7.0. Concentration of proteins in the
collected fractions was obtained by measuring the absorbance at 280
nm, and fractions that corresponded to the peak of maximal
absorbance were stored at -20◦C.
Generation of human denditic cells
Blood samples were obtained from 20 healthy non-smoker women
donors in the Fundación Hemocentro Buenos Aires, Argentina. Blood
was obtained by venipuncture of the forearm vein, and it was drawn
directly into heparinized plastic tubes. Mononuclear cells were isolated
from peripheral blood by Ficoll-Hypaque (1.077 g) density gradient
centrifugation (GE Healthcare, Uppsala, Sweden). CD14+ cells were
then isolated by positive selection according to the manufacturer's
instructions (Miltenyi Biotec, Bergisch Gladbach, Germany). The
purity was checked by FACS analysis using anti-CD14 monoclonal
antibody and was found to be higher than 95%. To obtain DC,
monocytes (106/ml) were cultured in RPMI 1640 medium
supplemented with 10% of heat-inactivated fetal calf serum (FCS)
(Gibco®, Life Technologies,Grand Island, NY, USA) 50 U/ml
penicillin, 50 μg/ml streptomycin (Invitrogen, Life Technologies,
Grand Island, NY, USA), 20 ng/ml interleukin (IL)-4, and 20 ng/ml
granulocyte macrophage-colony stimulating factor (GM-CSF)
(Immunotools, Friesoythe, Germany) during 5 days. To obtain mature
DC (mDC) (2 × 106) were cultured with lipopolysaccharide (LPS)
from E. coli (500 ng/ml) during 24 h at 37◦C. LPS untreated cells were
considered as immature DC (iDC) [17]. Before each experimental
procedure, cells were treated during 1 h with IgG in the absence or
presence of cholinergic antagonists (atropine or mecamylamine)
added 30 min before.
Flow cytometry
Cells were washed twice with phosphate buffer saline (PBS)
supplemented with 2% FCS and suspended in PBS supplemented with
10% heat-inactivated FCS. Fluorescein isothyocyanate (FITC) and
phycoerythrin (PE) conjugated monoclonal antibodies were added at
saturating concentrations for 30 min at 4 °C, and two additional
washes were performed. DC were stained with the following
monoclonal antibodies: FITC- or PE-conjugated monoclonal
antibodies directed to HLA-DR or CD86 respectively (BD
Pharmingen, San Diego, CA, USA). Analysis was performed by using a
FACS flow cytometer and CellQuest software (BD Biosciences, San
Jose, CA, USA).
Measurement of cytokine production
The production of cytokines: tumor necrosis factor alpha (TNF-α),
IL-12 and IL-10 was measured in cell culture supernatants by ELISA
(R&D Systems, Minneapolis, MN, USA).
Tumor cell extract
The human breast adenocarcinoma cell line MCF-7 was obtained
from the American Type Culture Collection (ATCC; Manassas, VI,
USA), and cultured in Dulbecco’s modified Eagle’s medium and F12
medium (DMEM:F12; 1:1; Invitrogen Inc., Carlsbad, CA, USA) with 2
mM L-glutamine, 80 mg/ml gentamycin, supplemented with 10% heat
inactivated FCS at 37ºC in a humidified 5% CO2 air. Cell cultures were
maintained as monolayers at 37ºC and 5% CO2 in DMEM medium
supplemented with 5% FCS. Confluent monolayers were detached
using the following buffer: 0.25% trypsin and 0.02% EDTA in Ca2+
and Mg2+ free PBS. The medium was replaced three times a week. Cell
viability was assayed by Trypan blue exclusion test, and the absence of
mycoplasma was confirmed by Hoechst staining [18]. To prepare cell
extracts, detached cells were lysed by triple freezing at -80◦C during 10
min alternated with thawing at 20◦C followed by centrifugation at 3000
rpm during 10 min [19]. Protein concentration was determined in the
supernatants by the method of Bradford [20] and saved at -20ºC.
Drugs
All drugs were purchased from Sigma Chemical Co (St. Louis, MI,
USA) unless otherwise stated. Solutions were prepared fresh daily.
Statistical analysis
Results are given as means ± S.E.M. of at least three independent
experiments. The statistical significance of differences between means
was calculated by the analysis of variance using GraphPad Prism 5; p
£0.05 was considered to be statistically significant. The analysis was
complemented by using the Tukey test to compare among mean
values. Differences between means were considered significant if p
£0.05.
Results
Effect of IgG on HLA-DR and CD86 expression by dendritic
cells
We have previously reported that IgG from breast cancer patients in
T1N0Mx promotes breast tumor progression by activating mAChR.
These receptors are also express in DC thus, DC may be sensitive to
the action of autoAbs. We analyzed the effect of IgG on DC obtained
from human monocytes cultured with IL-4 and GM-CSF for 5 days.
Then cells were stimulated with LPS to obtain mDC or cultured
without LPS, yielding iDC. As it was expected, mDC expressed higher
amounts of HLA-DR than iDC (Figure 1A). The addition of T1N0Mx-
IgG significantly reduced HLA-DR expression in mDC at all
concentrations tested (p<0.0001 vs. control) (Figures 1A and 2A). This
effect was reverted in the presence of 10-8M atropine but not by
mecamylamine (10-7M) (Table 1). Normal-IgG did not modify HLA-
DR expression in DC (Figure 1B).
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IgG (10-8M) IgG + AT (10-8M) IgG + MM (10-7M)
HLA-DR 72.5 ± 18.6 120.8 ± 18.0*** 77.7 ± 19.8
CD86 497.4 ± 26.3 655.9 ± 42.6** 490.2 ± 29.9
Mature dendritic cells were obtained by culturing cells with LPS (500 ng/ml)
during 24 h at 37°C. Then cells were treated during 1 hr with IgG from breast
cancer patients in T1N0Mx in the absence or presence of the muscarinic
antagonist atropine (AT) or the nicotinic antagonist mecamylamine (MM) added
30 min before IgG. The expression of HLA-DR and CD86 was measured by flow
cytometry. Data represent the mean ± S.E.M of 4 experiments. **p£0.001; ***p
£0.0001 vs. IgG.
Table 1: Effect of cholinergic antagonists on the IgG-modulated
expression of maturation markers in mature dendritic cells.
Figure 1: Modulation of the expression of HLA-DR and CD86 on
dendritic cells. Cells were obtained from human monocytes as it
was stated in Materials and Methods. Then, cells were cultured in
the absence or presence of LPS (500 ng/ml) to obtained inmature
(i) or mature (m) dendritic cells (DC) respectively. DC were
stimulated during 1 h with different concentrations of T1N0Mx-
IgG to analyze A) HLA-DR or C) CD86 expression. Also the effect
of normal-IgG on B) HLA-DR or D) CD86 expression in DC was
analyzed. Markers were measured by flow cytometry. Data
represent the mean fluorescence intensity ± S.E.M. (n=3).
*p<0.0001 vs. control iDC; #p<0.01 and ###p<0.0001 vs. control
mDC.
In addition, T1N0Mx-IgG also decreased the expression of CD86
(p<0.0001 vs. control) a co-stimulatory molecule, which is up-
regulated in mDC (Figure. 1C and 2B), and this effect was also
reverted by atropine (10-8M) (Table 1). Surprisingly, normal-IgG also
reduced CD86 expression in mDC (Figure. 1 D). No effects were
exerted by T1N0Mx-IgG or normal-IgG on iDC (Figure 1).
Effect of IgG on the production of cytokines by dendritic
cells
Further, we analyzed the effect of IgG on the production of
cytokines by DC. IgG from breast cancer patients reduced the
production of TNF-α in mDC at all concentrations tested (Figure. 3A).
The latter effect was reverted by the preincubation of cells with 10-8 M
atropine but not by mecamylamine (Table 2). In addition, autoAbs
increased TNF-α production by iDC only at 10-8M (p<0.001 vs.
control) effect that was totally blunted by atropine (10-8M) (IgG: 207
± 48 pg/ml; atropine plus IgG: 99 ± 25 pg/ml). Normal-IgG did not
modify TNF-α levels in DC supernatants (Figure 3 B).
Figure 2: Effect of T1N0Mx-IgG on the expression of HLA-DR and
CD86 in mature dendritic cells. Cells were stimulated during 1 h
with 10-8M T1N0Mx-IgG to analyze A) HLA-DR or B) CD86
expression. Histograms from one representative experiment of
three are shown.
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We also studied the effect of autoAbs on IL-12 production by DC.
Figure 3C shows that IgG from breast cancer patients significantly
increased IL-12 levels in mDC (p<0.0001; p<0.001 vs. control,
untreated mDC) (Figure. 3C). The effect of 10-8M IgG was
significantly reduced by preincubating cells with mecamylamine (10-8
M) (Table 2). Normal-IgG did not modify IL-12 levels in DC (Figure.
3D).
When we analyzed the effect of autoAbs on IL-10, an increment in
this cytokine levels was observed either in mDC or in iDC at all
concentrations tested (p<0.01) (Figure. 3E). Similarly to IL-12, the
preincubation of mDC with 10-8M mecamylamine significantly
reduced IgG’s action on mDC (p<0.001 vs. T1N0Mx-IgG) pointing to
nAChR participation in these actions (Table 2). Normal-IgG did not









TNF-α 2023.3 ± 494.1 3743.2 ± 449.5* 2632.4 ± 301.6
IL-12 761.1 ± 68 623.3 ± 134.4 417.4 ± 109.9**
IL-10 376.1 ± 65.6 318.3 ± 44.1 193.5 ± 19.1**
Mature dendritic cells were obtained by culturing cells with LPS (500 ng/ml)
during 24 h at 37°C. Then cells were treated during 1 h with IgG from breast
cancer patients in T1N0Mx in the absence or presence of the muscarinic
antagonist atropine (AT) or the nicotinic antagonist mecamylamine (MM) added
30 min before IgG. The production of cytokines was measured in cell culture
supernatants by ELISA. Data represent the mean ± S.E.M. of 4 experiments. *p
£0.01; **p£0.001 vs. IgG.
Table 2: Effect of cholinergic antagonists on the IgG-modulated
production of cytokines by mature dendritic cells.
Cytokine (pg/ml) Normal T1N0Mx
TNF-a 5.2 ± 1.3 21.9 ± 8.1*
IL-12 N.D. 43.4 ± 21.1***
IL-10 N.D. 116.1 ± 42.1***
Blood samples (10/20 ml) were obtained at routine procedures before surgery
after informed consent from patients classified in stage I (T1N0Mx) and from
women free of illness (Normal). Sera were separated and heat-inactivated at
56°C for 30 min and stored at -20°C. Cytokine levels were determined by
ELISA. Results are expressed as mean ± S.E.M. of 4 experiments. *p<0.01;
***p<0.0001 vs. normal sera. N.D: not detected
Table 3: Levels of cytokines in the sera of breast cancer patients in
stage I.
Levels of cytokines in the sera of breast cancer patients
In addition, we analyzed the levels of TNF-α, IL-12 and IL-10 in the
same sera from which autoAbs were purified. As it is shown in Table 3,
IL-10 and IL-12 which are not detectable in normal sera, dramatically
raised in the sera from breast cancer patients (p<0.0001 vs. normal),
while a modest increment in TNF-α was observed in the sera form
cancer patients (p<0.01 vs. normal).
Effect of breast tumor on the production of cytokines by
dendritic cells
Taking into account that the presence of tumor could be regulating
the activation of DC, we analyzed the effect of MCF-7 tumor extract
on iDC regarding the production of cytokines. As it is shown in Table
4 the treatment of iDC with MCF-7 breast tumor proteins (2.5 mg)
triggers the liberation of cytokines by iDC reaching similar levels to
those observed in mDC, mainly for IL-10 and IL-12 (p<0.0001 vs.
untreated iDC).
Figure 3: Modulation of cytokine production by dendritic cells.
Cells were obtained from human monocytes. Then, cells were
cultured in the absence or presence of LPS (500 ng/ml) to obtain
inmature (i) or mature (m) dendritic cells (DC) respectively. DC
were stimulated during 1 h with different concentrations of
T1N0Mx-IgG (A,C,E) or normal-IgG (B, D, F) to analyze TNF-α;
IL-12 or IL-10 respectively in culture supernatants by ELISA. Data
are expressed in picograms per milliliter (pg/ml) and represent the
mean±S.E.M of 6 experiments. *p<0.0001 vs. iDC; #p<0.01;
##p<0.001; ### p<0.0001 vs. control iDC or mDC.
Discussion
The presence of autoAbs against tumor associated antigens in the
sera of cancer patients has been reported previously. Several studies
reviewed by Fernandez Madrid et al. [12] indicate that a plethora of
autoAbs with different specificities have been found in breast cancer
patients. These spontaneous responses are frequently detected in 5 to
30% of patients for one autoantigen. Moreover, Chapman et al. [21]
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reported that the incidence of autoAbs, to at least one of six tumor
associated antigens (p53, c-myc, HER2, NYESO-1, BRCA2, and
MUC1) analyzed as a group raises to 64% in the sera of breast
carcinoma patients. These striking data imply that the human immune
system detects the tumor antigens as ‘‘nonself’’ and makes a humoral
immune response very early in this disease.
Cytokine (pg/ml) iDC iDC-bTE iDC/mDC
iDC-
bTE/mDC
TNF-a 65 ± 15 240 ± 44*** 0.022 0.083
IL-12 49 ± 17 190 ± 41*** 0.108 0.421
IL-10 38 ± 3 226 ± 46*** 0.169 1.004
Table 4: Production of cytokines by dendritic cells. Effect of breast
tumor extract.
We had described the presence of autoAbs against mAChR in
human and animal tumor bearers [13,22]. Our laboratory extensively
studied the function of autoAbs from breast cancer patients in stage I
as promoters of tumor progression [13-15]. Here, we described for the
first time, the ability of autoAbs to stimulate cholinergic receptors
expressed in DC exerting modulatory actions. Regarding maturation
markers, the decrement in HLA-DR and CD86 molecules induced by
autoAbs on mDC could be revealing a mechanism to produce an
immunosuppressive or tolerogenic profile via DC in breast cancer
patients. Previous results reported that DC generated from monocytes
obtained from early breast cancer patients showed a significantly lower
expression of the phenotype-associated antigens CD1a, CD83, CD80,
CD86 and CD54 than the DC from healthy controls, which also
reinforce our results [23].
We also observed that normal IgG exerted a negative effect on the
expression of CD86 in mDC. Antibodies that bind to a variety of
exogenous antigens, as well as self-antigens (i.e., nucleic acids,
phospholipids, and cellular components), account for a significant
proportion of Ig in healthy individuals. These antibodies are referred
to as natural antibodies or autoAbs, because they arise independently
of known and/or deliberate immunization. Since they recognize a
variety of self-antigens, they have a role in the development of the B-
cell repertoire and the homeostasis of the immune system [24]. We
cannot discard the presence of natural antibodies against cholinergic
receptors in healthy donors that could activate cholinergic receptors
expressed in iDC.
We observed that IgG from breast cancer patients altered cytokine
profile in DC. AutoAbs decreased TNF-α liberation, and stimulated
both IL-12 and IL-10 production in mDC. It must be taken into
account that it is usually accepted that iDC, after antigen-“danger
signal” become into mDC. However, recently it has been reported that
after the stimulation with, some drugs, microorganisms, or the tumor
microenvironment, iDC differentiation and/or mDC formation could
be altered [25-27]. The analysis of tumor infiltrating DC in murine
melanoma revealed the presence of myeloid and plasmacytoid DC
populations, most of these DC appeared immature, but about a third
expressed a mature phenotype [28]. These mDC might also induce T
cell tolerance, indicating a functional plasticity of mDC allowing them
to adopt either suppressive/tolerogenic or activating/immunogenic
phenotypes depending on the signals received [28].
We observed that the stimulation of mDC with IgG from breast
cancer patients decreased TNF-α levels and markedly increased IL-12
and IL-10 levels via nAChR activation. In line with our results, Nouri-
Shirazi and Guinet [29] proposed that nicotine can exert
immunosuppressive effect on immune surveillance through functional
impairment of the DC system.
Tolerogenic DC are characterized by a semimature phenotype, with
low levels of co-stimulatory molecules expression [30]. Moreover,
tolerogenic DC produce high levels of anti-inflammatory cytokines
resulting in the induction and expansion of regulatory T cells [30].
Precisely, the increment in DC-derived IL-10 levels produced by
autoAbs added to the inhibition of HLA-DR and CD86 expression
could be contributing to the down-regulation of Th1 response and to
the up-regulation of Th2 profile with a positive loop on B cells.
Concomitantly, IL-10 and IL-12 levels are up-regulated in the sera of
breast cancer patients in T1N0Mx, probably as a consequence of the
presence of tumor proteins, since the treatment of iDC with MCF-7
tumor extract triggered the production of IL-12, and in a more potent
manner of IL-10 almost reaching the levels of these cytokines
produced by mDC.
Conclusion
The results obtained in this work together with our previous
observations reveal a central role for cholinergic autoAbs since they
promote tumor growth either acting directly on tumor cells or via DC
system. Regarding the latter, here we demonstrate that autoAbs
modulate the function of DC by reducing maturation markers, as
HLA-DR and CD86 and the production of TNF-a, and by increasing
the liberation IL-10 and IL-12 by iDC, which in turn could be
worsening anti-tumor immune response in breast cancer patients.
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